References
- Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(3):414–422.
- Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn’s disease. Gastroenterology. 2020;159(1):139–147.
- Takenaka K, Kitazume Y, Fujii T, et al. Objective evaluation for treat to target in Crohn’s disease. J Gastroenterol. 2020;55(6):579–587.
- Kopylov U, Koulaouzidis A, Klang E, et al. Monitoring of small bowel Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2017;11(11):1047–1058.
- Dulai PS, Singh S, Vande CN, et al. Should We divide Crohn’s disease into ileum-dominant and isolated colonic diseases? Clin Gastroenterol Hepatol. 2019;17(13):2634–2643.
- Chetcuti ZS, Ellul P, Sidhu R. The role of small bowel endoscopy for Crohn’s disease. Curr Opin Gastroenterol. 2019;35(3):223–234.
- Cotter J, Dias DCF, Magalhaes J, et al. Validation of the Lewis score for the evaluation of small-bowel Crohn’s disease activity. Endoscopy. 2015;47(04):334– 335.
- Af BC, Nieminen U, Sipponen T, et al. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2013;48(5):543–551.
- Frei R, Fournier N, Zeitz J, et al. Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: 10-Year-Follow-up data from the swiss IBD cohort study. J Crohns Colitis. 2019;13(10):1292–1301.
- Jongsma M, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut. 2020;2020:339.
- Han ZM, Qiao WG, Ai XY, et al. Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn’s disease. Gastrointest Endosc. 2018;87(6):1489–1498.
- Vogel J, Da LMA, Baker M, et al. CT enterography for Crohn’s disease: accurate preoperative diagnostic imaging. Dis Colon Rectum. 2007;50(11):1761–1769.
- Bruining DH, Zimmermann EM, Loftus EJ, et al. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn’s disease. Radiology. 2018;286(3):776–799.
- Greener T, Klang E, Yablecovitch D, et al. The impact of magnetic resonance enterography and capsule endoscopy on the re-classification of disease in patients with known Crohn’s disease: a prospective israeli IBD research nucleus (IIRN) study. J Crohns Colitis. 2016;10(5):525–531.
- Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8(4):357–363.
- Dias DCF, Boal CP, Monteiro S, et al. Lewis score–prognostic value in patients with isolated small bowel Crohn’s disease. J Crohns Colitis. 2015;9(12):1146–1151.
- Gonçalves P, Magro F, Martel F. Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel. Inflamm Bowel Dis. 2015;21(2):453–467.
- Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14(5):694–709.